Document Detail


Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
MedLine Citation:
PMID:  22641239     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Denosumab, a fully human monoclonal antibody against RANK ligand, increased bone mineral density (BMD) and reduced fracture risk vs placebo in a phase 3 trial in men with prostate cancer on androgen deprivation therapy (ADT). The present analysis of this study evaluated BMD changes after 36 months in responder subgroups and in individual patients for three key skeletal sites (lumbar spine (LS), femoral neck (FN) and total hip (TH)) and the distal radius.
METHODS: Men with nonmetastatic prostate cancer receiving ADT were treated with subcutaneous denosumab 60 mg (n=734) or placebo (n=734) every 6 months for up to 36 months in a phase 3, randomized, double-blind study. Patients were instructed to take supplemental calcium and vitamin D. For this BMD responder analysis, the primary outcome measure was the percentage change in BMD from baseline to month 36 at the LS, FN and TH as measured by dual-energy X-ray absorptiometry. BMD at the distal 1/3 radius at 36 months was measured in a substudy of 309 patients.
RESULTS: At 36 months, significantly more patients in the denosumab arm had increases of >3% BMD from baseline at each site studied compared with placebo (LS, 78 vs 17%; FN, 48 vs 13%; TH, 48 vs 6%; distal 1/3 radius, 40 vs 7% (P<0.0001 for all)). BMD loss at the LS, FN and TH occurred in 1% of denosumab-treated patients vs 42% of placebo patients, and BMD gain at all three sites occurred in 69% of denosumab patients vs 8% of placebo patients. Lower baseline BMD was associated with higher-magnitude BMD responses to denosumab at the LS, FN and TH.
CONCLUSIONS: In men with prostate cancer receiving ADT, significantly higher BMD response rates were observed with denosumab vs placebo. Patients with lower baseline T-scores benefited the most from denosumab treatment.
Authors:
R B Egerdie; F Saad; M R Smith; T L J Tammela; J Heracek; P Sieber; C Ke; B Leder; R Dansey; C Goessl
Related Documents :
10872359 - Charnley low-frictional torque arthroplasty of the hip. 20-to-30 year results.
20720139 - Influence of obesity on femoral osteolysis five and ten years following total hip arthr...
16906119 - 21-year results of the uncemented fully textured lord hip prosthesis.
20376709 - Constrained liner in neurologic or cognitively impaired patients undergoing primary tha.
20666709 - Do we need to follow up primary total hip replacements?
10853899 - Short- and medium-term results of the thrust plate prosthesis in patients with polyarth...
1747839 - Arthroscopic débridement of the knee for osteoarthrosis.
16671489 - Clinical outcome of patients with idiopathic normal pressure hydrocephalus three years ...
23635049 - Penicillin to prevent recurrent leg cellulitis.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Prostate cancer and prostatic diseases     Volume:  15     ISSN:  1476-5608     ISO Abbreviation:  Prostate Cancer Prostatic Dis.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-10-12     Completed Date:  2012-12-18     Revised Date:  2013-09-03    
Medline Journal Info:
Nlm Unique ID:  9815755     Medline TA:  Prostate Cancer Prostatic Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  308-12     Citation Subset:  IM    
Affiliation:
Urology Associates Urologic Medical Research, Kitchener, Ontario, Canada. blairegerdie@mac.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Androgen Antagonists / therapeutic use*
Antibodies, Monoclonal, Humanized / pharmacology*,  therapeutic use
Antineoplastic Agents, Hormonal / therapeutic use*
Bone Density / drug effects*
Bone Density Conservation Agents / pharmacology*,  therapeutic use
Humans
Male
Middle Aged
Prostatic Neoplasms / drug therapy*
RANK Ligand / antagonists & inhibitors
Treatment Outcome
Grant Support
ID/Acronym/Agency:
K24 CA121990/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Androgen Antagonists; 0/Antibodies, Monoclonal, Humanized; 0/Antineoplastic Agents, Hormonal; 0/Bone Density Conservation Agents; 0/RANK Ligand; 4EQZ6YO2HI/denosumab
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dynamics of fluorescence depolarisation in star-shaped oligofluorene-truxene molecules.
Next Document:  A one-pot sequence for the efficient synthesis of highly functionalized macrocarbocycles or bridged ...